Clinical Trials
25 trialsNCT03595124 2026-05-27
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03172754 2026-05-22
Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
Fox Chase Cancer Center
Phase 1/2 Active not recruiting
NCT07227415 2026-05-22
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
Phase 1/2 Recruiting
NCT01334073 2026-05-14
EVAX
University Hospital, Bordeaux
Phase 1 Completed
NCT05805501 2026-05-12
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05327686 2026-05-04
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT05969496 2026-04-13
NEOPAX
University of Colorado, Denver
Phase 2 Recruiting
NCT05808608 2026-04-07
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
West China Hospital
Phase 1/2 Active not recruiting
NCT07500831 2026-03-30
Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma
Qilu Hospital of Shandong University
Phase NA Not yet recruiting
NCT07123090 2026-03-25
SPARCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05738694 2026-03-17
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT07469683 2026-03-13
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Yonsei University
Phase 2 Recruiting
NCT06860386 2026-03-06
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Suspended
NCT07383441 2026-02-03
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
SWOG Cancer Research Network
Phase 3 Not yet recruiting
NCT02853331 2026-02-02
KEYNOTE-426
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03092856 2025-12-17
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
University of Southern California
Phase 2 Active not recruiting
NCT07277972 2025-12-11
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05363631 2025-12-10
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
University of Iowa
Phase 1/2 Active not recruiting
NCT05287464 2025-11-26
International Multicentric Study ARON-1
Hospital of Macerata
Recruiting
NCT04370509 2025-11-19
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
Phase 2 Terminated
NCT03438708 2025-10-02
PADRES
University of California, San Diego
Phase 2 Active not recruiting
NCT07172386 2025-09-16
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT04458259 2025-08-28
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT04522323 2025-07-25
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
MedImmune LLC
Phase 1 Active not recruiting